Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04754542 · ClinicalTrials.gov registry record
Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS): Extension of the DISCOMS Study
A clinical trial, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- 76
- Enrollment target
NCT04754542 is a clinical trial that has completed, run by University of Colorado, Denver. The registered enrollment target is 76 participants.
The verdict
NCT04754542 has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- 76 participants
- Enrollment target
Study Summary
The Main Hypothesis of this extension trial is that among those who have successfully discontinued their DMT as part of the DISCOMS trial (i.e. did not have a new MS relapse or brain MRI lesion) and remain off DMT after DISCOMS are at no greater risk of new or worsened MS disease activity compared to those who successfully continued their DMT as part of DISCOMS and remain on DMT, each assessed at least one year after termination of the primary DISCOMS study.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2021-05-18 |
| Est. Completion | 2022-11-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04754542
The ClinicalTrials.gov registry entry for NCT04754542 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04754542 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04754542 about?
NCT04754542 is a clinical study titled "Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS): Extension of the DISCOMS Study". The Main Hypothesis of this extension trial is that among those who have successfully discontinued their DMT as part of the DISCOMS trial (i.e. did not have a new MS relapse or brain MRI lesion) and remain off DMT after DISCOMS are at no greater risk of new or worsened MS disease activity compared t...
What is the current status of trial NCT04754542?
This trial is currently completed. The enrollment target is 76 participants. The study started on 2021-05-18. Estimated completion is 2022-11-30.
Who is sponsoring clinical trial NCT04754542?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.